Luis Paz-Ares

Sep 10, 2023 | ascopubs.org | Helena A. Yu |James Yang |Martin Reck |Luis Paz-Ares

After tumor progression with EGFR TKI therapy and PBC in patients with EGFR -mutated NSCLC, HER3-DXd once every 3 weeks demonstrated clinically meaningful efficacy with durable responses, including in CNS metastases. A phase III trial in EGFR- mutated NSCLC after progression on an EGFR TKI is ongoing (HERTHENA-Lung02; ClinicalTrials.gov identifier: NCT05338970 ).

Sep 10, 2023 | brnw.ch | Helena A. Yu |James Yang |Martin Reck |Luis Paz-Ares

For patients with epidermal growth factor receptor (EGFR)–mutated advanced non–small-cell lung cancer (NSCLC), initial treatment typically includes one or two EGFR tyrosine kinase inhibitor (TKI) regimens comprising either a third-generation EGFR TKI or a first- or second-generation EGFR TKI followed by a third-generation EGFR TKI when the EGFR T790M mutation is detected.1 After disease progression on EGFR TKI therapy, patients are usually treated with platinum-based chemotherapy (PBC; with...

Jun 28, 2023 | onclive.com | Luis Paz-Ares

Luis Paz-Ares, MD, PhD, chairman, Medical Oncology Department, Hospital Doce de Octubre; head, Lung Cancer Unit, CNIO (National Oncology Research Center); associate professor, Universidad Complutense, discusses efficacy and safety findings from the phase 2 CARMEN-LC05 trial (NCT04524689) of tusamitamab ravtansine (SAR408701) in patients with nonsquamous non–small cell lung cancer (NSCLC) with CEACAM5 expression.